Great post. There isn’t huge upside from a shareholder perspective if you sell something for $50m, then use the next 2 years spending it, before doing the same again.
The big upside of course is if their partners get any of these drugs approved.
Having said that, for the company to be still existing at all is amazing given that Bronchitol is a complete damp squib. Chiesi must be wondering why they bothered.
Ann: Quarterly Shareholder Update - December 2017, page-10
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
